언어 선택

SN38

SN38 제품 목록

속성
Antibody (3)
제품 라이브러리
온라인 (3)
종
Mouse (3)
태그
- (3)
마커
Unconjugated (1)HRP Labeled (1)Biotin-labeled (1)

제품 번호	종	발현 시스템	제품 설명
SN8-BVM808	Mouse	HEK293	Biotinylated Anti-SN38 Antibody, Mouse IgG1, Avitag™
SN8-M685	Mouse	HEK293	Monoclonal Anti-SN38 Antibody, Mouse IgG1
SN8-PLM685	Mouse	HEK293	HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1

총 수량3

SN38분자 배경

Dxd (Exatecan ADC derivative) is a potent DNA topoisomerase I inhibitor with an IC50 of 0.31 uM for targeting ADCs (DS-8201A). Dxd was cytotoxic to human tumor cell lines KPL-4, NCI-N87 and SK-BR, 3 and the IC50s of MDA-MB-468 was 1.43 NM-4.07 nM, while lgGADC (Dxd as payload) had no inhibitory effect on HER2 expression in the 4 cell lines. DS8201a (Dxd as payload) had a significant inhibitory effect on HER2-positive KPL-4 and NCI cell lines N87 and SK-BRwith IC50 values of 26.8, 25.4 and 6.7 ng/mL, respectively, but had no inhibitory effect on MDA MB-468 (IC50, > 10000 - mL). HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA.

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
ALXN-2220	ALXN2220; ALXN-2220; NI006; NI-006	Phase 3 Clinical	AstraZeneca global R & D (China) Co Ltd	Cardiomyopathies; Transthyretin amyloidosis	상세
Nexiguran ziclumeran	NTLA-2001	Phase 3 Clinical	Intellia Therapeutics Inc	Amyloidosis, Familial; Amyloid Neuropathies, Familial; Peripheral Nervous System Diseases; Metabolism, Inborn Errors; Polyneuropathies; Genetic Diseases, Inborn; Metabolic Diseases; Cardiomyopathies; Amyloidosis; Nervous System Diseases; Neuromuscular Diseases; Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Amyloid Neuropathies; Transthyretin amyloidosis	상세
NNC6019-0001	NNC6019-0001; NNC-6019; PRX-004	Phase 2 Clinical	Novo Nordisk A/S	Cardiomyopathies; Transthyretin amyloidosis	상세
NI-006	NI-006	Phase 1 Clinical	Neurimmune Ag	Cardiomyopathies; Transthyretin amyloidosis	상세
Nucresiran	ALNTTRsc-04	Phase 1 Clinical	Alnylam Pharmaceuticals Inc	Transthyretin amyloidosis	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Patisiran	SAR-438037; GENZ-438027; ALN-TTR02; ALN-18328	Approved	Alnylam Pharmaceuticals Inc	Onpattro	United States	Amyloid Neuropathies, Familial	Alnylam Pharmaceuticals Inc	2018-08-10	Amyloidosis, Familial; Amyloid Neuropathies, Familial; Polyneuropathies; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies	상세
Vutrisiran	ALN-TTRSC02	Approved	Alnylam Pharmaceuticals Inc	AMVUTTRA	United States	Amyloid Neuropathies, Familial; Transthyretin amyloidosis	Alnylam Pharmaceuticals Inc	2022-06-13	Amyloidosis, Familial; Amyloid Neuropathies, Familial; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis	상세
Acoramidis	AG-10; ALXN-2060; ALXN 2060; BBP-265	Approved	Stanford University	Attruby	United States	Transthyretin amyloidosis	Bridgebio Pharma Inc	2024-11-22	Polyneuropathies; Heart Diseases; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies	상세
Inotersen sodium	ISIS-420915; GSK-2998728	Approved	Ionis Pharmaceuticals Inc	Tegsedi	EU	Amyloidosis	Akcea Therapeutics Ireland Ltd	2018-07-05	Adenomatous Polyposis Coli; Amyloid Neuropathies, Familial; Amyloidosis; Transthyretin amyloidosis	상세
Tafamidis	PF-6291826; Fx-1006A; PF-06291826; FX-1006A	Approved	Pfizer Inc	维万心, VYNDAMAX	United States	Heart Diseases	Foldrx Pharmaceuticals Inc	2019-05-03	Heart Diseases; Transthyretin amyloidosis	상세
Eplontersen	IONIS-TTR-LRx; AKCEA-TTR-LRx; ION-682884; ION-TTR-LRx	Approved	Ionis Pharmaceuticals Inc	WAINUA	United States	Transthyretin amyloidosis	Astrazeneca Ab	2023-12-21	Amyloid Neuropathies, Familial; Cardiomyopathies; Transthyretin amyloidosis	상세
Tafamidis Meglumine	FX-1006A; PF-6291826; Fx-1006A; PF-06291826	Approved	Pfizer Inc	维达全, Vyndaqel	EU	Amyloidosis	Pfizer Europe Ma Eeig	2011-11-16	Amyloid Neuropathies, Familial; Immunoglobulin Light-chain Amyloidosis; Cardiomyopathies; Amyloidosis; Transthyretin amyloidosis; Amyloid Neuropathies	상세